Longeveron LLC (LGVN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Longeveron LLC (LGVN) has a cash flow conversion efficiency ratio of -0.384x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.65 Million) by net assets ($14.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Longeveron LLC (LGVN) market capitalisation for the company's overall valuation and market capitalisation.
Longeveron LLC - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Longeveron LLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Longeveron LLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Longeveron LLC ranked by their cash flow conversion efficiency. See how well can Longeveron LLC service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Grid Metals Corp
V:GRDM
|
-165.526x |
|
Highway 50 Gold Corp
V:HWY
|
-0.013x |
|
Carbonxt Group Ltd
AU:CG1
|
-0.146x |
|
NOMADAR Corp. Class A Common Stock
NASDAQ:NOMA
|
-0.042x |
|
Morgan Sindall Group PLC
LSE:MGNS
|
-0.017x |
|
CHINA NEW ENERGY LS-00025
F:9H5
|
N/A |
|
Shui-Mu International Co Ltd
TW:8443
|
0.015x |
|
Kobexindo Tractors Tbk
JK:KOBX
|
0.622x |
Annual Cash Flow Conversion Efficiency for Longeveron LLC (2018–2025)
The table below shows the annual cash flow conversion efficiency of Longeveron LLC from 2018 to 2025. View current stock price of Longeveron LLC for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.67 Million | $-18.64 Million | -3.285x | -418.52% |
| 2024-12-31 | $21.89 Million | $-13.87 Million | -0.634x | +77.52% |
| 2023-12-31 | $6.74 Million | $-19.00 Million | -2.819x | -313.74% |
| 2022-12-31 | $20.50 Million | $-13.97 Million | -0.681x | -164.81% |
| 2021-12-31 | $37.45 Million | $-9.64 Million | -0.257x | +78.70% |
| 2020-12-31 | $1.96 Million | $-2.36 Million | -1.208x | -124.58% |
| 2019-12-31 | $4.45 Million | $-2.39 Million | -0.538x | +29.22% |
| 2018-12-31 | $6.81 Million | $-5.18 Million | -0.760x | -- |
About Longeveron LLC
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; com… Read more